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Abstract
Background: Loss to follow-up after a positive infant HIV diagnosis negates the potential benefits of robust policies
recommending immediate triple antiretroviral therapy initiation in HIV positive infants. Whilst the diagnosis and
follow-up of HIV positive infants in urban, specialized settings is easier to institutionalize, there is little information
about access to care amongst HIV positive children diagnosed at primary health care clinic level. We sought to
understand the characteristics of HIV positive children diagnosed with HIV infection at primary health care level,
across all provinces of South Africa, their attendance at study-specific exit interviews and their reported uptake of
HIV-related care. The latter could serve as a marker of knowledge, access or disclosure.
Methods: Secondary analysis of data gathered about HIV positive children, participating in an HIV-exposed
infant national observational cohort study between October 2012 and September 2014, was undertaken. HIV
infected children were identified by total nucleic acid polymerase chain reaction using standardized
procedures in a nationally accredited central laboratory. Descriptive analyses were conducted on the HIV
positive infant population, who were treated as a case series in this analysis. Data from interviews
conducted at baseline (six-weeks post-delivery) and on study exit (the first visit following infant HIV positive
diagnosis) were analysed.
Results: Of the 2878 HIV exposed infants identified at 6 weeks, 1803 (62.2%), 1709, 1673, 1660, 1680 and
1794 were see at 3, 6, 9, 12, 15 and 18 months respectively. In total, 101 tested HIV positive (67 at 6 weeks,
and 34 postnatally). Most (76%) HIV positive infants were born to single mothers with a mean age of 26
years and an education level above grade 7 (76%). Although only 33.7% of pregnancies were planned, 83%
of mothers reported receiving antiretroviral drugs to prevent MTCT. Of the 44 mothers with a documented
recent CD4 cell count, the median was 346.8 cell/mm3. Four mothers (4.0%) self-reported having had TB.
Only 59 (58.4%) HIV positive infants returned for an exit interview after their HIV diagnosis; there were no
statistically significant differences in baseline characteristics between HIV positive infants who returned for an
exit interview and those who did not. Amongst HIV positive infants who returned for an exit interview, only
two HIV positive infants (3.4%) were reportedly receiving triple antiretroviral therapy (ART). If we assume that
all HIV positive children who did not return for their exit interview received ART, then ART uptake amongst
these HIV positive children < 18 months would be 43.6%.
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Conclusions: Early ART uptake amongst children aged 15 months and below was low. This raises questions
about timely, early paediatric ART uptake amongst HIV positive children diagnosed in primary health care
settings. Qualitative work is needed to understand low and delayed paediatric ART uptake in young children,
and more work is needed to measure progress with infant ART initiation at primary care level since 2014.
Introduction
Although there has been a reduction in new HIV infections
amongst children aged 0–14, at the end of 2016, approxi-
mately 2.1 (1.7–2.6) million children were infected with hu-
man immunodeficiency virus (HIV); 90% of them lived in
sub-Saharan Africa [1–3]. Although interventions to pre-
vent mother to child transmission of HIV (PMTCT) have
successfully reduced new paediatric HIV infections, paedi-
atric HIV has not been eliminated [4]. Without treatment,
paediatric HIV is a rapidly progressive disease, with high
mortality [5]. Since the introduction of triple antiretroviral
therapy (ART), and particularly early ART, infant survival
rates have significantly improved [1, 2, 5, 6]; however, the
proportion of children accessing treatment remains un-
acceptably low. [6, 7]. Although ART coverage for HIV
positive children aged 0–14 years increased globally from
28% in 2009 to 74% in 2015, and in South Africa from 29%
in 2010 to 55% in 2016, ART uptake amongst young chil-
dren under the age of 2 years is unknown [3, 8, 9]. In re-
source limited settings, not all HIV exposed children
receive timely and appropriate infant HIV diagnostics and
referral into care; this compromises early treatment [1, 7].
In South Africa, task shifting, decentralization of HIV treat-
ment and nurse initiated management of antiretroviral
therapy (NIMART) have been implemented to scale-up
coverage of HIV care. Data demonstrate that NIMART re-
duces waiting times, loss to follow-up, transport costs and
opportunity costs, provides care closer to patients’ homes,
and increases retention in care [10–12]. By 2010 manage-
ment of paediatric HIV infection was included in the South
African chart booklet of the Integrated Management of
Childhood Illness (IMCI) strategy, and guidelines recom-
mended ART for all HIV positive infants (children less than
1 year); by 2013 ART eligibility criteria expanded to include
all HIV positive children under the age of 5 years [13, 14].
This paper describes the characteristics of HIV positive
children aged 6weeks to 18months, spread across geo-
graphical settings nationally in South Africa, their attendance
at study-specific primary health care clinic exit interviews
and their uptake of HIV-related care. This provides a deeper
understanding of access to care for HIV positive children at-
tending routine, non-specialised health services.
Methods
Study design
Secondary analysis of data from HIV positive infants was
undertaken. The data were drawn from a nationally
representative prospective observational cohort study of
HIV exposed infants (HEI), followed up between Octo-
ber 2012 and September 2014 to establish 18-month
mother to child transmission of HIV (MTCT) and HIV-
free survival. This cohort was established from a nation-
ally representative survey conducted at 580 primary
health care clinics / community health centres across all
nine provinces of South Africa to measure MTCT at 4–
8 weeks postpartum. During the survey, multistage prob-
ability proportional to size sampling methodology was
used to establish a nationally and provincially represen-
tative sample. Hospitals were excluded from the sam-
pling frame to reduce the bias posed by sick populations,
and because hospitals do not routinely offer
immunization; our sample was drawn from 6 week
immunization service points, which have > 95% immun-
isation coverage. All infants receiving their six-week
immunization in selected facilities and their mothers/
caregivers were recruited, either consecutively (in facil-
ities without long immunization queues) or systematic-
ally (in facilities with long immunization queues based
on desired sample size for the day and number of eli-
gible mother/infant pairs in the queue). Infant dried
blood spot samples were collected from all consented in-
fants (and not only from infants brought by self-reported
HIV positive mothers or whose mothers received inter-
ventions to prevent MTCT) and tested at the National
Institute for Communicable Diseases (NICD), National
Health Laboratory Services for HIV antibody to ascertain
HIV exposure. Antibody positive infants or those born
to self-reported HIV positive mothers were tested for
HIV infection using total nucleic acid polymerase chain
reaction (TNA PCR). A closed cohort of HIV antibody
positive infants (HEI) was established, and all HEI were
subsquently seen at 3-monthly intervals from three until
18 months. At each study visit, mothers / primary carr-
givers were interviewed and HEI were tested for HIV
(TNA PCR). As per national policy, the laboratory
returned all infant HIV test results to their clinic of ori-
gin within 1 month. Routine clinic (not research) nurses
were required to return results to mothers/parents, con-
firm the diagnosis and initiate paediatric ART. As per
national policy, all children with confirmed HIV infec-
tion were eligible for ART, regardless of their CD4 cell
count. Results at the 6 week time point have been re-
ported elsewhere[15–17]. and details about how the HIV
infected population differs from the rest of the cohort
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are addressed in the overall 18-month MTCT and HIV-
free survival paper, which is currently under review.
More information about loss to follow-up in the HIV ex-
posed cohort, from which the HIV infected children
came, are provided in the paper by Ngandu et.al. in this
series. For this paper, given that confirmation of the in-
fant’s HIV status would have been complete within 1
month of the blood-taking visit, we expected that HIV
positive infants should have received HIV-related care
(including ART) before they were seen at the next visit,
which was scheduled 3 months later. The study visit 3
months after an infant HIV positive diagnosis, or as soon
as possible to the 3 month post HIV diagnosis time
point if the mother could not be contacted at this time
point, was the study exit interview for HIV positive in-
fants. This visit aimed to check that the infant was in
HIV-related care, as infant HIV diagnosis was the study
endpoint.
Study population
HIV exposed infants enrolled in the follow-up study at
4–8 weeks postpartum, and diagnosed with HIV infec-
tion at six-weeks, or at 3, 6, 9, 12 or 15 months were eli-
gible for this analysis. All infant HIV diagnoses were
made at primary health care level, as hospitals were ex-
cluded from the sampling frame.
Data collection methods
Maternal and infant baseline information was obtained
from the 4–8week interview. Data on infant birth weight
and gestational age was obtained from the infant’s Road to
Health booklet (RTHB), a patient-held booklet issued at
birth to all infants born in South Africa. Questions on in-
fant medication were asked at every interview, specifically
about infant antiretroviral drug use. A food and medication
diary was issued to all HEI at the enrolment visit to assist
with recall about medicine and feeding. This diary allowed
the mother/caregiver to keep a daily log of medicine and
food ingested. The data collector reviewed and collected
the diary during each interview. All study exit interviews
were conducted at primary health care clinics / community
health centers until January 2014; thereafter a non-health
facility follow-up site, based on mother’s choice, was
allowed. If an HIV positive infant missed the scheduled
study exit interview they were invited for interviews at all
subsequent time points until they attended the study exit
interview, or until the infant reached 18months, whichever
came first. Trained research nurses conducted the study
exit interview. All study exit interviews were scheduled to
coincide with routine child follow-up visits. For mothers
who did not return for study exit interviews, data collectors
documented the reason for non-return, where possible.
Three attempts (telephone calls on three different occa-
sions) were made to contact each mother to return for a
study exit interview. Data collectors searched ART clinic re-
cords or registers to ascertain whether children with missed
study exit interviews were on ART.
Data analysis
Data were analysed using STATA version 14. As num-
bers were small, unweighted descriptive analysis was
conducted to explore and understand baseline character-
istics of HIV infected infants (at 4–8 weeks postpartum)
and uptake of study exit interviews and ART. Chi-square
tests were used for categorical variables (Fisher’s exact
test, if expected cell count< 5; Cochran-Armitage, for or-
dinal data with one binary variable) and t-tests or Wil-
coxon two-sample test for continuous parametric or
non-parametric data, respectively. All p-values are 2-
sided.
Ethics approval and consent to participate
Ethics approval for this secondary analysis was obtained
from the University of Pretoria Ethics Committee. The
main study was approved by the South African Medical
Research Council Ethics Committee and the Centers for
Disease Control and Prevention. All HIV positive infants
who were not on ART during the study exit interview
were referred to routine services for ART initiation. Al-
though visits were synchronized with routine clinic
visits, caregiver-infant pairs received R100 (approxi-
mately 8USD) per visit, as an inconvenience allowance
to cover their travel and opportunity costs.
Results
Of the 2878 HIV exposed infants identified at 6 weeks,
1803 (62.6%) were seen at 3 months, 1709, 1673, 1660,
1680 and 1794 were see at 3, 6, 9, 12, 15 and 18months
respectively. In total, 101 tested HIV positive (67 at 6
weeks, and 34 postnatally). HIV positive infants were
born at an average gestation of 38 weeks ranging from
24 to 42 weeks with a mean birth weight of 2.8 kg. Of
these infants, 18% were born before 37 weeks gestation
and 20/101 (19.8%) had birth weights less than 2.5 kg.
Most of these 101 HIV positive infants were born to sin-
gle mothers (76.2%), with a mean age of 26.7 years, grade
8–12 education (75.2%) and poor access to basic amen-
ities. Approximately three-quarters (75.2%) had access to
piped water, 50.5% had a pit latrine and 79.2% used elec-
tricity as the main source of energy (data not shown).
Most caregivers travelled to clinic on foot (57.4%) with
an average travelling time of 27 min (range 2–120 min)
(data not shown). Socioeconomic circumstances were
suboptimal: 24% of caregivers reported cutting the size
of their meals due to non-availability of food. Only a
third (33.7%) of pregnancies were reported as planned.
There was poor integration between mother and infant
care and between infant immunisation and HIV care (data
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not shown). Most mothers (74.3%) reported receiving sup-
port (from a health care worker or family member) during
pregnancy and delivery (data not shown). Most mothers
(62.42%) were not yet on lifelong ART. Of the 44 mothers
who knew their CD4 cell count the median was 346.8 cell/
mm3. Four of the 101 mothers, (4.0%) self-reported that
they had been diagnosed with TB disease by 6 weeks
postpartum.
Of the 101 HIV positive infants we were able to trace
59 (57.6%) to conduct a study exit interview (Table 1).
Of the HIV positive infants who did not present for
study exit interview (n = 42), approximately a third (n =
13) died between the 6 and 12- month interview, and
the rest were difficult to contact (38%), refused further
follow up (28%) or had relocated (2%), data not shown.
There were no significant differences between HIV posi-
tive infants who presented for a study exit interview and
those who did not (Table 1). Of the 59 seen for a study
exit interview, only 34 (57.6%) were seen 3 months after
the infant’s HIV positive diagnosis. The remainder were
difficult to trace, and seen at later time points (Table 2).
Amongst the 59 children who attended the study exit
interview, 88.1% (52/59) were brought by their mothers.
Of the infants not brought by mothers, caregivers re-
ported that mothers were alive but not available on the
day of the interview. Prior access to HIV-related care
amongst infants attending study exit visits, was non-ex-
istent or delayed (Table 2); only two caregivers (3.4%) re-
ported that their HIV positive child was on ART.
Discussion
Using data from a nationally representative study to de-
termine MTCT and HIV-free survival at 3, 6, 9, 12, 15
and 18 months, we demonstrate poor uptake of study
exit interviews and extremely low ART uptake (3.4%),
despite guidelines recommending ART initiation as soon
as possible in HIV positive children < 5 years. If we hy-
pothesise 100% ART uptake amongst children who did
Table 1 Univariate analysis of factors associated with returning for a study exit interview amongst HIV positive infants aged 6 weeks
till 18 months, South Africa, 2012–2014
Characteristics Category Returned for study exit interview n = 59 Did not return for study exit interview n = 42 P
Number Mean/Proportion 95% CI Number Mean/Proportion 95% CI
Mean Age 59 26.9 ± 5.4a [25.6, 28.3] 41 26.3 ± 6.7a [24.2, 28.4] 0.74
Marital status Single 45 76.3 [63.5, 85.6] 32 76.2 [60.7, 86.9] 0.99
Other 14 23.7 [13.9, 35.4] 10 23.8 [12.2, 37.0]
Meal Cut in size due to poor
socio-economic circumstances
Yes 14 23.7 [13.1–39.3] 10 23.8 [13.1, 39.3] 0.99
No 45 76.3 [63.5, 85.6] 32 76.2 [60.7, 86.9]
Maternal Education 0 up to Grade 7 18 30.5 [20.0, 43.6] 6 14.6 [6.6, 29.4] 0.06
Grade 8 and above 41 79.5 [56.4, 80.0] 35 85.4 [70.6,93.4]
Experienced discrimination
due to HIV status
Yes 8 16.3 [8.2, 29.8] 3 9.4 [2.9, 26.1] 0.36
No 41 83.7 [70.2, 91.8] 29 90.6 [73.9, 97.1]
Disclosure to friend or family Yes 41 69.5 [57.4, 80.0] 28 66.7 [50.9, 79.4] 0.77
No/other 18 30.5 [20.0, 43.6] 14 33.3 [20.6, 49.1]
Infant hospitalised by 6 weeks
for ≥1 nights
Yes 3 5.1 [1.6, 14.9] 2 4.9 [1.2 18.0] 0.96
No 56 94.9 [85.1, 98.4] 39 95.1 [82.0, 98.8]
Mother hospitalised between 6
and 14 weeks for ≥1 night
Yes 1 2.6 [0.03, 17.6] 0 0 – 0.32
No 37 97.4 [82.4, 99.7] 11 100.0 –
Mother on ART Yes 25 51.0 [37, 64.9] 13 40.6 [24.8, 58.6] 0.4
No 40 49 [35.1, 63.0] 19 59.4 [41.4, 75.2]
Infant had difficulty breathing
in last 2 weeks
Yes 6 10.2 [4.6, 21.1] 3 7.3 [2.3, 20.9] 0.62
No 53 89.8 [78.9, 95.4] 38 92.7 [79.297.7]
Infant had diarrhoea in last
2 weeks
Yes 1 1.7 [0.2, 1.1] 3 7.3 [2.3, 20.8] 0.21
No 58 98.3 [88.5, 99.9] 38 92.7 [79.2, 97.7]
Time travelling to clinic (mins) 59 27.8 ± 18.3 [23.0, 32.6] 42 25.6 ± 14.2 [21.2,30.0] 0.50
Infants birth weight (kg) 59 2.8 ± 0.53 [2.7, 3.0] 41 2.8 ± 0.55 [2.6, 3.0] 0.98
Infants gestation at birth 43 37.9 ± 2.3 [37.2, 38.6] 28 37.9 ± 3.2 [36.6,39.1] 0.79
Infants weight at 6 weeks 54 4.4 ± 0.76 [4.21,4.6] 38 4.22 ± 0.9 [3.9,4.5] 0.20
astandard deviation
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Table 2 Timing of infant HIV positive test, timing of study exit interview and access to infant HIV-related care
Timing of study exit interview Infant HIV positive detected at 6-week (4–8 weeks) HIV test N = 67
Had a study exit interview,
Number, No, (%)









3months 19 (28.3) 15 1 1 1
6 months 7 (10.4) 7 1 1 1
9 months 2 (3.0) 2 0 0 0
12 months 5 (7.5) 5 0 0 0
15 months 3 (4.5) 2 0 0 0
18 months 1 (1.5) 1 0 0 0
Total positives at 6 weeks with study exit
interview
37/67 (55.2) 32/37 (86.5%) 2/37 (5.4) 2 (5.4) 2 (5.4)
Infant became HIV positive between > 8 weeks and 19 weeks, detected at 3 month visit N = 18
Had a study exit interview, No
(%)









6months 7 (38.8) 6 0 0 0
9 months 0 0 0 0 0
12 months 1 (5.6) 1 0 0 0
15 months 1 (5.6) 1 0 0 0
18 months 0 0 0 0 0
Total positives at 3 months with study exit
interview
9/18 (50.0%) 8/9 (88.9%)
Infant became HIV positive between > 3 and 6months, detected at 6 month visit N = 6
Had a study exit interview, n
(%)









9months 2 (33.2) 2 0 0 0
12 months 1 (16.7) 1 0 0 0
15 months 1 (16.7) 1 0 0 0
18 months 1 (16.7) 1 0 0 0
Total positives at 6 months with study exit
interview
5/6 (83.3) 5/5 (100%)
Infant became HIV positive between > 6 and 9months, detected at 9 month visit N = 4
Had a study exit interview, n
(%)









12 months 3 (75.0) 2 0 0 0
15 months 0(0) 0 0 0 0
18 months 0(0) 0 0 0 0
Total positives at 9 months with study exit
interview
3/4 (75.0) 2/3 (66.7%) 0 0 0
Infant became HIV positive between > 9 and 12 months, detected at 12 month visit N = 4
Had a study exit interview, n
(%)









15 months 3(75%) 3 0 0 0
18 months 0 0 0 0 0
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not attend the study exit interview paediatric ART up-
take would have been 43.6% (44 children). This uptake is
still sub-optimal. Given that we found no significant dif-
ferences in baseline characteristics between infants who
returned for study exit interview and those who did not,
we postulate that 100% ART uptake in the latter group
is highly unlikely. Thus, 43.6% is likely to be an over-es-
timate of early ART uptake. The poor ART uptake may
have been because mothers were waiting for the study
nurse to counsel and advise them, or were afraid to take
their children to the clinic timeously, or that clinics were
still waiting for the confirmatory HIV result, or were still
in the process of pre-ART counselling and preparation.
Delays in receipt of infant HIV test results have
been reported in South Africa, [18]. An observational
PMTCT cohort study conducted at Rahima Moosa
Mother and Child hospital, Johannesburg between
August 2008 and December 2010 demonstrated a
median delay interval of 10 weeks recorded between
a positive six-week HIV PCR test and initiation of
ART with median ART initiation age at 16 weeks of
age[19, 20]. At the time of our study UNAIDS esti-
mated that paediatric ART coverage was 49%
amongst children less than 14 years in South Africa,
compared with a more than 90% ART coverage
amongst pregnant women.[4] Our results for chil-
dren less than 18 months of age are significantly
below this modelled national estimate either because
the modelled estimate looks at overall access to ART
amongst children, and not early access in the first
18 months of life, or due to small numbers of HIV
positive children in our study.
Since the discussion of these results at national
PMTCT Technical working groups, the National Insti-
tute for Communicable Diseases implemented a system
that sends out weekly reports to each district, to facili-
tate tracing of HIV. positive children. The impact of this
system remains to be determined.
Our work has several limitations. Although this was a
large prospective study drawn from a nationally repre-
sentative sample of HIV exposed infants, recruited from
580 randomly selected primary health care facilities
around South Africa, the number of HIV positive chil-
dren was small, and analysis did not account for survey
design. This, together with the small proportion who
returned for study exit interview precluded detailed
modelling, and may have biased our assessment of ART
uptake. Additionally, all data on ART uptake were self-
reported and non-uptake could reflect that the infant
was not on ART or that the mother/caregiver did not re-
port that the child was on ART. This is unlikely given
the rapport and relationship that developed between
mothers and data collectors from recruitment at 6
weeks, and the fact that we used food and medication
diaries. We were unable to search laboratory databases to
ascertain access to ART or viral suppression, as we did
not document infant names in the research database, and
had no identifier that linked our study number with a la-
boratory number. Data collectors had no success finding
HIV positive children in clinic ART records/registers.
Amongst the HIV positive infants who died, we do not
know their ART uptake and response to treatment.
Conclusions
Our results emphasise the need to strengthen primary
health care systems for early paediatric HIV-related care
in the first 18 months post-delivery. For policy makers,
and at programmatic level, we recommend strengthen-
ing outreach systems to find and support HIV positive
children and their families[21–23], as poor ART know-
ledge and false perceptions of high ART costs have been
identified as barriers to care and treatment in developing
countries [2, 7, 10, 24]. Community-level workers could
help overcome these barriers. For primary health care fa-
cilities, we recommend integrating maternal and child
health services to reduce the number of separate visits
for each, and investing in regular systematic community-
based tracing of HIV positive children [7, 24]. Further
quantitative and qualitative research is needed to under-
stand uptake of paediatric ART and reasons for delayed
or poor uptake and adherence.
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ART: antiretroviral therapy; HEI: HIV exposed infant; HIV: human
immunodeficiency virus; IMCI: Integrated Management of Childhood Illness;
Table 2 Timing of infant HIV positive test, timing of study exit interview and access to infant HIV-related care (Continued)
Total positives at 12 months with study exit
interview
3/4 (75%) 3/3 (100%) 0 0 0
Infant became HIV positive between > 12 and 15 months, detected at 15 month
visit N = 2










Total positives at 15 months with study exit
interview at 18 months
2 (100) 2 (100%) 0 0 0
TOTAL 59/101 (58.4%) 52/59 (88.1%)a 2 (3.4%) 2 (3.4%) 2 (3.4%)
aFor the 7 infants not brought by mother, mother was alive but not available on day of interview. 67 infections detected at 6 weeks and 34 detected postnatally
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transmission of HIV; TNA PCR: total nucleic acid polymerase chain reaction
Declarations
The findings and conclusions in this report are those of the authors and do
not necessarily represent the official position of the funding agencies.
About this supplement
This article has been published as part of BMC Infectious Diseases Volume 19
Supplement 1, 2019: Evaluating the effectiveness of national programmes to
prevent vertical HIV transmission: Methods, results and implications for PMTCT
Option B+ from South Africa. The full contents of the supplement are
available online at https://bmcinfectdis.biomedcentral.com/articles/
supplements/volume-19-supplement-1.
Authors’ contributions
Conceptualisation of the paper and providing overall leadership and
mentorship for the writing of this paper (AG); Data analysis (AG and SO);
writing the first draft of the paper and approving the final version (EM);
providing intellectual input to all drafts including the final draft (all authors).
All authors read and approved the final manuscript.
Funding
This paper was supported by the President’s Emergency Plan for AIDS Relief
(PEPFAR) through the Centers for Disease Control and Prevention, under the
terms of Cooperative Agreement Number 1U2GPS001137 and
1U2GGH001150 provided both technical and financial support; UNICEF and
the South African National AIDS Council also provided financial support. This
work was supported by the South African Medical Research Council
(SAMRC). Publication costs were funded by the SAMRC. The views in this
paper do not represent those of the funding agencies.
Availability of data and materials
Data are available from the authors upon request.
Consent for publication
Consent for publication was obtained from the Centers for Disease Control
and Prevention, and from all authors.
Competing interests
The authors declare that they have no competing interests.
Author details
1Mamelodi Hospital, Pretoria 0112, South Africa. 2Department of Paediatrics,
University of Pretoria, Pretoria 0001, South Africa. 3Biostistics Unit, South
African Medical Research Council, Pretoria 0001, South Africa. 4Health
Section, United Nations Children’s Fund (UNICEF), New York, NY 10017, USA.
5School of Public Health, University of the Western Cape, Cape Town 7535,
South Africa. 6Division of Global HIV and Tuberculosis, Center for Global
Health, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
7Health Systems Research Unit, South African Medical Research Council,
Pretoria 0001, South Africa. 88 HIV Prevention Research Unit, South African
Medical Research Counci, Durban 3630, South Africa.
Published: 16 September 2019
References
1. Desmonde S, Essanin J, Aka A, Messou E, Amorissani-Folquet M, Rondeau V.
Morbidity and health care resource utilization in HIV infected childrenafter
antiretroviral therapy intiation in cote d’Ivoire, 2004-2009. J Acquir Immune
Defic Syndr. 2014;65(3):95–103.
2. Auyo P, Musick B, Lui H, Braitstein P, Nyandiko W, Otieno-Nyunya B.
Frequency and factors associated with adherence to and completion of
combination antiretroviral therapy for prevention of mother to child
transmission in western Kenya. J Int AIDS Soc. 2013;16(3):17994.
3. UNAIDS. UNAIDS Data 2017. In: UNAIDS; 2017. Available from http://
aidsdatahub.org/unaids-data-2017-unaids-2017-0. accessed 9 Aug 2018.
4. UNAIDS. Global Plan progress report. 2015. Available from http://www.
unaids.org/en/resources/documents/2015/JC2774_2015ProgressReport_
GlobalPlan. Accessed 5 June 2018.
5. Violari A, Cotton M, Gibb D, Babiker A, Steyn J, Madhi S, et al. Early
antiretroviral therapy and mortality among HIV-infected infants. N Engl J
Med. 2008;359:2233–44.
6. Abrams E, Simonds R, Modi S, Rivadeneira E, Vaz P, Kankasa C, et al. PEPFAR
scale-up of paediatric HIV services: innovations, achievements, and
challenges. J Acquir Immune Defic Syndr. 2012;60(3):105–12.
7. Braun M, Kabue M, McCollum E, Ahmed S, Kim M, Artker L, et al. Inadequate
co ordination of maternal and infant HIV services detrimentally affects early
infant diagnosis outcomes in Lilongwe, Malawi. J Acquir Immune Defic
Syndr. 2011;56(5):122–8.
8. UNICEF. For every child end AIDS: seventh stocktaking report, 2016.
Available from https://data.unicef.org/wp-content/uploads/2016/12/HIV-and-
AIDS-2016-Seventh-Stocktaking-Report.pdf. Accessed 4 June 2018.
9. Nyasulu J, Muchiri E, Mazwi S, Ratshefola M. NIMART rollout to primary
healthcare facilities increases access to antiretrovirals in Johannesburg: an
interrupted time series analysis. S Afr Med J. 2013;103(4):232–6. https://doi.
org/10.7196/SAMJ.6380.
10. Tran D, Shakeshaft A, Ngo A, Rule J, Wilson D, Zhang L, et al. Structural
barriers to timely initiation of antiretroviral treatment in Vietnam: findings
from six outpatient clinics. PLoS One 2012 ;7(12):e51289; 7(12).
11. Kredo T, Ford N, Adeniyi F, Garner P. Decentralising HIV treatment in lower
and middle-income countries (review). Cochrane database of systematic
reviews 2013.
12. Emdin C, Milson P. A systematic review evaluating the impact of task
shifting on access to antiretroviral therapy in sub-Saharan Africa. Afr Health
Sci. 2012;12(3):318–48.
13. National Department of Health and SANAC. Clinical Guidelines: PMTCT
(Prevention of Mother-to-Child Transmission). 2010. Available from https://
www.fidssa.co.za/Content/Documents/PMTCT_Guidelines.pdf. Accessed 4
Aug 2019.
14. National Department of Health. The south African antiretroviral treatment
guidelines 2013: PMTCT guidelines revised march 2013. Government
Printers; 2013. Available from https://www.westerncape.gov.za/assets/ndoh_
pmtct_guidelines.pdf. Accessed 4 Aug 2019.
15. Goga A, Dinh T, Jackson D, Lombard C, Puren A, Sherman G, et al.
Population-level effectiveness of maternal antiretroviral treatment initiation
before or during the first trimester and infant antiretroviral prophylaxis on
early mother-to-child transmission of HIV, South Africa: implications for
eliminating MTCT. J Glob Health. 2016; http://www.jogh.org/documents/
issue201602/jogh-06-020405.pdf.
16. Goga AE, Dinh TH, Jackson DJ, Lombard C, Delaney KP, Puren A, Sherman
G, Woldesenbet S, Ramokolo V, Crowley S, Doherty T, Chopra M, Shaffer N,
Pillay Y for the South African PMTCT Evaluation (SAPMTCTE) Team. First
population-level effectiveness evaluation of a national programme to
prevent HIV Transmission from mother to child, South Africa. J Epidemiol
Community Health. 2015;69:240–48. doi: https://doi.org/10.1136/jech-2014-2
045352014.
17. Goga A, Jackson D, Lombard C, Ramokolo V, Ngandu N, Sherman G, et al.
Highest risk of mother-to-child transmission of HIV or death in the first 6
months postpartum: results from 18 month follow-up of an HIV-exposed
national cohort, South Africa - Abstract number: A-792-0314-06477. AIDS
2016. Durban; 2016.
18. Kenny J, Mulenga V, Hoskins S, Scholten F, Gibb D. The needs for HIV treatment
and care of children, adolescents, pregnant women and older people in low-
income and middle-income countries. AIDS. 2012;26(Suppl 2):105–16.
19. Lilian R, Kalk E, Bhowan K, Berrie L, Carmona C, Technau K, et al. Early
diagnosis of in-utero and intrapartum HIV infection in infants prior to 6
weeks of age. J Clin Microbiol. 2012;50:7.
20. Ghadrshenas A, Amor Y, Chang J, Dale H, Sherman G, Vojnov L, et al. Improved
access to early infant diagnosis is a critical part of child centric prevention of
mother-to-child transmission agenda. AIDS. 2013;27(Suppl 2):197–205.
21. Sivapalasingam S, Mendillo M, Ahmed A, Mwamzuka M, Said S, Marshed F,
et al. The importance of caregivers in the outcome of paediatric HIV
management, Mombasa, Kenya. AIDS Care. 2014;26(4):425–33.
22. Lallemant M, Chang S, Cohen R, Pecoul B. Paediatric HIV- a neglected
disease? N Engl J Med. 2011;365:581–3.
23. Bhardwaj S, Barron P, Pillay Y, Treger-Slavin L, Robinson P, Goga A, et
al. Elimination of mother to child transmission of HIV in South Africa:
Mathivha et al. BMC Infectious Diseases 2019, 19(Suppl 1):790 Page 7 of 8
rapid scale-up using quality improvement. . S Afr Med J 2014; 104(3):
Suppl1: 239–243.
24. Posse M, Meheus F, Van Asten H, Van Der Ven A, Baltusesen R. Barriers to
access to anteretroviral treatment in developing countries: a review. Tropical
Med Int Health. 2008;13(7):904–13.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Mathivha et al. BMC Infectious Diseases 2019, 19(Suppl 1):790 Page 8 of 8
